Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ISAAC TAFUR

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1679536387
CMS profile
30754
Location
LUBBOCK, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$472.12

20 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $472.12 20

By paying entity

PY2024 · entire year · sorted by reported total

Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ISAAC TAFUR

NPI 1679536387 · CMS profile ID 30754

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

LUBBOCK, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1679536387?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ISAAC TAFUR, NPI 1679536387, CMS profile ID 30754. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679536387?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ISAAC TAFUR, NPI 1679536387, CMS profile ID 30754. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679536387?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ISAAC TAFUR, NPI 1679536387, CMS profile ID 30754, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1679536387?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

20 matching records · $472.12 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 20 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–20 of 20.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Daiichi Sankyo Inc. $23.1612/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089488514 CMS
ABBVIE INC. $16.6012/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106194690 CMS
ABBVIE INC. $16.1111/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106194688 CMS
PFIZER INC. $24.3711/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131381200 CMS
Janssen Biotech, Inc. $32.7610/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078738255 CMS
Janssen Biotech, Inc. $19.8510/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078738053 CMS
Genentech USA, Inc. $23.2910/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133022706 CMS
AstraZeneca Pharmaceuticals LP $23.3709/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104291734 CMS
Celgene Corporation $21.6608/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101125796 CMS
Genmab U.S., Inc. $21.8908/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126827322 CMS
Amgen Inc. $32.8308/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111720793 CMS
Adaptive Biotechnologies Corporation $27.9208/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150262890 CMS
PFIZER INC. $29.5207/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131346497 CMS
Janssen Biotech, Inc. $32.3306/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078739552 CMS
JAZZ PHARMACEUTICALS INC. $29.3205/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150226693 CMS
Celgene Corporation $24.9805/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101125792 CMS
AstraZeneca Pharmaceuticals LP $18.9205/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105669281 CMS
PFIZER INC. $20.9904/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131317688 CMS
Genentech USA, Inc. $18.4204/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133022702 CMS
ABBVIE INC. $13.8304/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106194686 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $828.42 56
PY2020 $118.08 9
PY2021 $138.59 9
PY2022 $11.97 1
PY2023 $96.84 6
PY2024 $472.12 20
PY2025 $636.04 26

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $24,700.00 2
PY2024 Principal investigator $850.00 2
PY2023 Principal investigator $16,152.90 11
PY2022 Principal investigator $75,305.83 35
PY2021 Principal investigator $57,088.81 68
PY2020 Principal investigator $164,987.76 78
PY2019 Principal investigator $218,143.35 88

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

68 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $2,500.00 12/21/2021 Covered Recipient Teaching Hospital
Covenant Medical Center
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA No dispute reported 06/30/2026 832681419
Principal investigator 1 Seagen Inc. $455.00 12/16/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 792667985
Principal investigator 1 Seagen Inc. $2,500.00 11/23/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 792667983
Principal investigator 1 Seagen Inc. $500.00 11/23/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer (MOUNTAINEER) No dispute reported 06/30/2026 792667989
Principal investigator 1 Incyte Corporation $1,000.00 09/15/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831059863
Principal investigator 1 Seagen Inc. $1,000.00 09/02/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 792667955
Principal investigator 1 Exelixis Inc. $500.00 08/31/2021 Non-covered Recipient Entity
Methodist Childrens Hospital dba Covenant Childrens Hospital
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838854121
Principal investigator 1 Seagen Inc. $500.00 08/17/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 792667963
Principal investigator 1 Seagen Inc. $633.24 08/17/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 792667965
Principal investigator 1 PFIZER INC. $312.54 08/03/2021 Covered Recipient Teaching Hospital
Covenant Medical Center
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA No dispute reported 06/30/2026 832743229
Principal investigator 1 PFIZER INC. $859.63 08/03/2021 Covered Recipient Teaching Hospital
Covenant Medical Center
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA No dispute reported 06/30/2026 832814371
Principal investigator 1 Incyte Corporation $3,000.00 07/07/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831059857
Principal investigator 1 Seagen Inc. $949.86 06/17/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 792667925
Principal investigator 1 Seagen Inc. $3,000.00 06/16/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer (MOUNTAINEER) No dispute reported 06/30/2026 792667937
Principal investigator 1 Seagen Inc. $240.32 05/26/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 792667931
Principal investigator 1 Seagen Inc. $500.00 05/12/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer (MOUNTAINEER) No dispute reported 06/30/2026 792667935
Principal investigator 1 Incyte Corporation $10.80 05/10/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831059641
Principal investigator 1 Incyte Corporation $26.84 05/10/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831059647
Principal investigator 1 Incyte Corporation $22.94 05/10/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831059653
Principal investigator 1 Incyte Corporation $17.90 05/10/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831059659
Principal investigator 1 Incyte Corporation $20.06 05/10/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831059665
Principal investigator 1 Incyte Corporation $10.80 05/10/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831059803
Principal investigator 1 Incyte Corporation $10.80 05/10/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831059809
Principal investigator 1 Incyte Corporation $22.94 05/10/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831059815
Principal investigator 1 Incyte Corporation $17.90 05/10/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831059821
Principal investigator 1 Incyte Corporation $10.80 05/10/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831059827
Principal investigator 1 Incyte Corporation $10.80 05/10/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831059833
Principal investigator 1 Incyte Corporation $10.80 05/10/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831059839
Principal investigator 1 Incyte Corporation $1.82 05/03/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205) No dispute reported 06/30/2026 831059671
Principal investigator 1 Incyte Corporation $28.30 05/03/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205) No dispute reported 06/30/2026 831059677
Principal investigator 1 Incyte Corporation $30.15 05/03/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205) No dispute reported 06/30/2026 831059683
Principal investigator 1 Incyte Corporation $38.64 05/03/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205) No dispute reported 06/30/2026 831059689
Principal investigator 1 Incyte Corporation $30.15 05/03/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205) No dispute reported 06/30/2026 831059845
Principal investigator 1 Incyte Corporation $40.20 05/03/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205) No dispute reported 06/30/2026 831059851
Principal investigator 1 Seagen Inc. $1,000.00 04/28/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer (MOUNTAINEER) No dispute reported 06/30/2026 792667933
Principal investigator 1 Seagen Inc. $500.00 04/21/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 792667929
Principal investigator 1 Seagen Inc. $750.00 04/14/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 792667927
Principal investigator 1 Incyte Corporation $22.94 04/08/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831059601
Principal investigator 1 Incyte Corporation $31.88 04/08/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831059605
Principal investigator 1 Incyte Corporation $26.84 04/08/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831059611
Principal investigator 1 Incyte Corporation $53.70 04/08/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831059617
Principal investigator 1 Incyte Corporation $10.80 04/08/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831059623
Principal investigator 1 Incyte Corporation $20.06 04/08/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831059629
Principal investigator 1 Incyte Corporation $17.90 04/08/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831059635
Principal investigator 1 Incyte Corporation $22.94 04/08/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831059743
Principal investigator 1 Incyte Corporation $10.80 04/08/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831059749
Principal investigator 1 Incyte Corporation $10.80 04/08/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831059755
Principal investigator 1 Incyte Corporation $10.80 04/08/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831059761
Principal investigator 1 Incyte Corporation $22.94 04/08/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831059767
Principal investigator 1 Incyte Corporation $10.80 04/08/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831059773
Principal investigator 1 Incyte Corporation $26.84 04/08/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831059779
Principal investigator 1 Incyte Corporation $10.80 04/08/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831059785
Principal investigator 1 Incyte Corporation $17.90 04/08/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831059791
Principal investigator 1 Incyte Corporation $22.94 04/08/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) No dispute reported 06/30/2026 831059797
Principal investigator 1 PFIZER INC. $4,777.51 04/08/2021 Non-covered Recipient Entity
COVENANT HEALTH SYSTEM
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA No dispute reported 06/30/2026 832754877
Principal investigator 1 PFIZER INC. $625.08 04/08/2021 Non-covered Recipient Entity
COVENANT HEALTH SYSTEM
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA No dispute reported 06/30/2026 832877495
Principal investigator 1 Seagen Inc. $2,144.78 04/07/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 792667919
Principal investigator 1 Seagen Inc. $79.31 03/17/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 792667897
Principal investigator 1 PFIZER INC. $1,000.00 03/13/2021 Non-covered Recipient Entity
COVENANT HEALTH SYSTEM
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA No dispute reported 06/30/2026 832854603
Principal investigator 1 Seagen Inc. $3,000.00 03/10/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Screening protocol to detect HER2 alterations required for enrollment on clinical research protocols of tucatinib No dispute reported 06/30/2026 792667913
Principal investigator 1 Seagen Inc. $100.00 03/03/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 792667905
Principal investigator 1 Seagen Inc. $250.00 02/24/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 792667895
Principal investigator 1 Seagen Inc. $455.00 02/22/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 792667903
Principal investigator 1 Seagen Inc. $500.00 02/22/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer (MOUNTAINEER) No dispute reported 06/30/2026 792667911
Principal investigator 1 Seagen Inc. $16,417.21 02/03/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 792667889
Principal investigator 1 Seagen Inc. $3,979.31 02/03/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 792667891
Principal investigator 1 Seagen Inc. $100.00 02/03/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 792667893
Principal investigator 1 Seagen Inc. $2,245.70 01/25/2021 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 792667901